DK0724877T3 - Blanding af fenofibrat og vitamin E samt terapeutisk anvendelse heraf - Google Patents
Blanding af fenofibrat og vitamin E samt terapeutisk anvendelse herafInfo
- Publication number
- DK0724877T3 DK0724877T3 DK96400133T DK96400133T DK0724877T3 DK 0724877 T3 DK0724877 T3 DK 0724877T3 DK 96400133 T DK96400133 T DK 96400133T DK 96400133 T DK96400133 T DK 96400133T DK 0724877 T3 DK0724877 T3 DK 0724877T3
- Authority
- DK
- Denmark
- Prior art keywords
- fenofibrate
- vitamin
- micronisate
- mixture
- therapeutic use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9501216A FR2730231B1 (fr) | 1995-02-02 | 1995-02-02 | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0724877T3 true DK0724877T3 (da) | 2000-10-16 |
Family
ID=9475777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96400133T DK0724877T3 (da) | 1995-02-02 | 1996-01-19 | Blanding af fenofibrat og vitamin E samt terapeutisk anvendelse heraf |
Country Status (10)
Country | Link |
---|---|
US (1) | US5880148A (da) |
EP (1) | EP0724877B1 (da) |
JP (1) | JP4746726B2 (da) |
AT (1) | ATE194078T1 (da) |
DE (1) | DE69608974T2 (da) |
DK (1) | DK0724877T3 (da) |
ES (1) | ES2148694T3 (da) |
FR (1) | FR2730231B1 (da) |
GR (1) | GR3034147T3 (da) |
PT (1) | PT724877E (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0925061B1 (en) | 1996-08-22 | 2005-12-28 | Jagotec Ag | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
AU1809499A (en) * | 1997-12-10 | 1999-06-28 | Awadhesh K. Mishra | Self-emulsifying fenofibrate formulations |
EP1079808B1 (en) | 1998-05-29 | 2004-02-11 | Skyepharma Canada Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
DK1105096T3 (da) * | 1998-08-19 | 2004-03-08 | Skyepharma Canada Inc | Injicerbare vandige propofoldispersioner |
US20060240070A1 (en) * | 1998-09-24 | 2006-10-26 | Cromack Keith R | Delivery of highly lipophilic agents via medical devices |
WO2000030616A1 (en) | 1998-11-20 | 2000-06-02 | Rtp Pharma Inc. | Dispersible phospholipid stabilized microparticles |
US6368622B2 (en) | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19910682B4 (de) * | 1999-03-10 | 2004-09-02 | Dierkes, Jutta, Dr. | Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie |
CA2270306C (en) * | 1999-04-27 | 2000-09-26 | Bernard Charles Sherman | Pharmaceutical compositions comprising co-micronized fenofibrate |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
CN1174741C (zh) * | 1999-09-21 | 2004-11-10 | Rtp药品公司 | 生物活性物质的表面改性微粒组合物 |
FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
US6682761B2 (en) | 2000-04-20 | 2004-01-27 | Rtp Pharma, Inc. | Water-insoluble drug particle process |
EP1320362B1 (en) * | 2000-09-20 | 2011-08-31 | Jagotec AG | Stabilised fibrate microparticles |
US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
HUP0303566A3 (en) * | 2000-10-26 | 2005-05-30 | Fournier Lab Ireland Ltd | Pharmaceutical composition containing combination of fenofibrate and coenzyme q10 and its use for the treatment of endothelial dysfunction |
AU2002221765B2 (en) * | 2000-10-26 | 2006-09-07 | Fournier Laboratories Ireland Limited | Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
DK1353696T3 (da) * | 2001-01-26 | 2007-04-10 | Schering Corp | Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer |
ATE357216T1 (de) * | 2001-02-22 | 2007-04-15 | Jagotec Ag | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen |
GB0114532D0 (en) * | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
EP1429756B1 (en) * | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
AU2003208238A1 (en) * | 2002-03-11 | 2003-09-22 | TAYLOR, , Carla | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
FR2845602B1 (fr) * | 2002-10-11 | 2005-07-08 | Servier Lab | Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
EP1569623B1 (en) * | 2002-12-13 | 2008-10-15 | Jagotec Ag | A topical nanoparticulate spironolactone formulation |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
FR2851734B1 (fr) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
ES2318274T3 (es) * | 2003-03-07 | 2009-05-01 | Schering Corporation | Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia. |
EP1601668B1 (en) * | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
CA2517573C (en) * | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
JP2006273849A (ja) * | 2005-03-02 | 2006-10-12 | Aska Pharmaceutical Co Ltd | フェノフィブラート含有組成物 |
WO2006102359A2 (en) * | 2005-03-23 | 2006-09-28 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
MX2007012124A (es) * | 2005-03-30 | 2007-11-21 | Teva Pharma | Formulaciones mejoradas de fenofibrato. |
US20070148233A1 (en) * | 2005-12-28 | 2007-06-28 | Lerner E I | Pharmaceutical formulations of fenofibrate having improved bioavailability |
KR20070113289A (ko) * | 2005-03-30 | 2007-11-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 멘톨 또는 peg/폴록사머를 함유하는 개선된페노피브레이트 제제 |
EP1707197A1 (en) | 2005-03-30 | 2006-10-04 | Teva Pharmaceutical Industries Ltd. | Formulations containing fenofibrate and a surfactant mixture |
JP4818637B2 (ja) * | 2005-05-02 | 2011-11-16 | 日本メナード化粧品株式会社 | 低密度リポタンパク質(ldl)酸化抑制剤 |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
US20070015833A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing menthol |
ES2325450T3 (es) | 2005-12-28 | 2009-09-04 | Teva Pharmaceutical Industries Ltd | Formulaciones farmaceuticas de fenofibrato con una biodisponibilidad mejorada. |
CA2718416C (en) * | 2008-03-13 | 2018-01-02 | Mallinckrodt Inc. | Multi-function, foot-activated controller for imaging system |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
CN102458373A (zh) | 2009-05-27 | 2012-05-16 | 株式会社三养生物制药 | 生物利用度提高的包含难溶性药物的微球及其制备方法 |
US20110217369A1 (en) * | 2009-09-03 | 2011-09-08 | Ranbaxy Laboratories Limited | Fenofibrate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2014091318A1 (en) | 2012-12-11 | 2014-06-19 | Lupin Atlantis Holdings, S.A. | Reduced dose pharmaceutical compositions of fenofibrate |
EP3046551B1 (en) | 2013-09-18 | 2020-08-05 | Georgetown University | Treating neurodegenerative disease with fenofibrate and analogs thereof |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792855A (fr) * | 1971-12-16 | 1973-06-15 | Ici Ltd | Compositions pharmaceutiques agissant sur le taux de cholesterol dans le sang |
JPS57188587A (en) * | 1981-05-15 | 1982-11-19 | Tanabe Seiyaku Co Ltd | Thienyloxazolylacetic acid derivative and its preparation |
ATE62414T1 (de) * | 1984-01-28 | 1991-04-15 | Roshdy Ismail | Mittel zur behandlung von herzerkrankungen. |
EP0344820B1 (de) * | 1984-01-28 | 1995-05-24 | Roshdy Dr. Ismail | Mittel zur Behandlung von Herzerkrankungen |
FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
US4859703A (en) * | 1987-06-15 | 1989-08-22 | Warner-Lambert Company | Lipid regulating compositions |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
US5662934A (en) * | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
JP3848380B2 (ja) * | 1993-12-14 | 2006-11-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | α−トコフェロール誘導体の製造法 |
-
1995
- 1995-02-02 FR FR9501216A patent/FR2730231B1/fr not_active Expired - Fee Related
-
1996
- 1996-01-19 DE DE69608974T patent/DE69608974T2/de not_active Expired - Lifetime
- 1996-01-19 PT PT96400133T patent/PT724877E/pt unknown
- 1996-01-19 AT AT96400133T patent/ATE194078T1/de active
- 1996-01-19 DK DK96400133T patent/DK0724877T3/da active
- 1996-01-19 EP EP96400133A patent/EP0724877B1/fr not_active Expired - Lifetime
- 1996-01-19 ES ES96400133T patent/ES2148694T3/es not_active Expired - Lifetime
- 1996-01-29 JP JP04787596A patent/JP4746726B2/ja not_active Expired - Fee Related
- 1996-02-02 US US08/594,658 patent/US5880148A/en not_active Expired - Lifetime
-
2000
- 2000-08-08 GR GR20000401842T patent/GR3034147T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69608974D1 (de) | 2000-08-03 |
GR3034147T3 (en) | 2000-11-30 |
DE69608974T2 (de) | 2001-02-08 |
JP4746726B2 (ja) | 2011-08-10 |
US5880148A (en) | 1999-03-09 |
JPH08253416A (ja) | 1996-10-01 |
FR2730231B1 (fr) | 1997-04-04 |
FR2730231A1 (fr) | 1996-08-09 |
EP0724877A1 (fr) | 1996-08-07 |
ES2148694T3 (es) | 2000-10-16 |
EP0724877B1 (fr) | 2000-06-28 |
PT724877E (pt) | 2000-12-29 |
ATE194078T1 (de) | 2000-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0724877T3 (da) | Blanding af fenofibrat og vitamin E samt terapeutisk anvendelse heraf | |
ES2150663T3 (es) | Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina. | |
DE3779500D1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
ATE200481T1 (de) | Beschränkte 9-cis-retinoide | |
FI933557A (fi) | Dimer av en molekylvariant av apolipoprotein samt foerfaranden foer dessframstaellning | |
ES2145545T3 (es) | Medicamentos que fomentan la circulacion sanguinea gastrointestinal. | |
NO940035D0 (no) | Kolesterolester, samt anvendelse av slike estere | |
DE69302883T2 (de) | L-Carnitin- und Alkanoyl-L-Carnitin-Ester mit Glykolsäure oder ihre Ester und diese enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen | |
DK515489A (da) | Dispergerbar laegemiddelformulering | |
EP0702557A4 (en) | INHIBITORS OF SMOOTH VASCULAR MUSCLE CELLS FOR THERAPEUTIC USE | |
ATE174221T1 (de) | Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten | |
ES2111104T3 (es) | Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer. | |
DK0488928T3 (da) | Pharmaceutiske formuleringer, der indeholder en blanding af højere, primære, alifatiske alkoholer, til behandling af hyperc | |
ES2010161A4 (es) | Utilizacion de una mezcla para el tratamiento de la alopecia | |
WO2003045311A3 (en) | Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts | |
DK1037629T3 (da) | Kombination af et retinsyremetabolismeblokerende middel og en tocopherol | |
KR910007531A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료 | |
DK0378146T3 (da) | Polyamin-derivater som antineoplastiske midler | |
ES2054011T3 (es) | Un proceso para la preparacion de un compuesto, "leualacina". | |
AU7025087A (en) | Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base | |
AR005249A1 (es) | Cromanilsulfonil (tio) ureas sustituidas, procedimiento para prepararlas, su utilizacion para preparar medicamentos y medicamentos que las contienen | |
ES2105453T3 (es) | Procedimiento para la preparacion de acido 5-fluoro-antranilico. | |
JPS5425409A (en) | Reduction gear | |
IT1247508B (it) | Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa |